Patents Assigned to GlaxoSmithKline LLC
  • 6-amino-purin-8-one compounds
    Patent number: 8067426
    Abstract: Compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: November 29, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
  • Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
    Patent number: 8063078
    Abstract: Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P?, n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: November 22, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Harshad Kantilal Rami, Mervyn Thompson
  • Chemical compounds
    Patent number: 8063071
    Abstract: The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKK?) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 22, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jeffrey K. Kerns, Qi Jin, Michael Lindenmuth, Sonia M Thomas, Katherine L. Widdowson
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8062665
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 22, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
    Patent number: 8058282
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: November 15, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jerry L. Adams, Jeffrey C. Boehm, Ralph Hall, Qi Jin, Jiri Kasparec, Domingos J. Silva, John J. Taggart
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052994
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X. Muller, Shivakumar G. Kapsi
  • 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052995
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
    Patent number: 8052993
    Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: November 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Francis X Muller, Shivakumar G Kapsi
  • Chemical compounds
    Patent number: 8026262
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: September 27, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, Andrew Larkin, Huiquiang Zhou, Eugene L. Stewart, Katherine Stetson, Darryl Lynn McDougald, Amarjit Sab Randhawa, John A. Ray
  • sEH inhibitors and their use
    Patent number: 8008483
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: August 30, 2011
    Assignee: Glaxosmithkline, LLC
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, Jr.
  • Inflammatory mediator antagonists
    Patent number: 8003101
    Abstract: The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: August 23, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Paul F. Life, Edward S. Rees, Andrew D. Rhodes
  • sEH inhibitors and their use
    Patent number: 7994317
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 9, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Yun Ding, Joseph Paul Marino, Jr., Peng Li, Allyn T. Londregan, Barry A. Morgan
  • Use of a p38 kinase inhibitor for treating psychiatric disorders
    Patent number: 7989479
    Abstract: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: August 2, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Methods for identifying compounds of interest using encoded libraries
    Patent number: 7989395
    Abstract: The present invention provides a method for identifying a compound of interest by screening libraries of molecules which include an encoding oligonucleotide tag.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: August 2, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Barry Morgan, Stephen Hale, Christopher C. Arico-Muendel, Matthew Clark, Richard Wagner, David I. Israel, Malcolm L. Gefter, Dennis Benjamin, Nils Jakob Vest Hansen, Malcolm J. Kavarana, Steffen Phillip Creaser, George J. Franklin, Paolo A. Centrella, Raksha A. Acharya
  • 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
    Patent number: 7981903
    Abstract: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Stanley Dawes Chamberlain, Felix Deanda, Jr., Roseanne Gerding, Masaichi Hasegawa, Kevin Kuntz, Huangshu Lei, Yasushi Miyazaki, Naohiko Nishigaki, Samarjit Patnaik, Aniko Redman, John Brad Shotwell, Kirk Stevens, Joseph Wilson, Bin Yang
  • Peptide deformylase inhibitors
    Patent number: 7982053
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Jeffrey Michael Axten, Jesus R. Medina
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 7982005
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Compounds
    Patent number: 7977344
    Abstract: The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: July 12, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Linos Lazarides, Stephen Allan Smith, Richard Stocker, Colin Jack Theobald
  • Nasal dilator
    Patent number: D644324
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: August 30, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jeffrey S. Brunner, Gustav R Fenton, Snigdha Mishra
  • Nasal dilator
    Patent number: D644325
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: August 30, 2011
    Assignee: GlaxoSmithKline, LLC
    Inventors: Jeffrey S. Brunner, Gustav R Fenton, Snigdha Mishra